Daiichi Sankyo Records ¥354 Billion Valuation Loss From Price Drop In Ranbaxy Shares
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo announced Jan. 5 a valuation loss of ¥354 billion for the fiscal quarter ending Dec. 31; the loss is associated with a more than 50 percent price drop in Ranbaxy shares the company acquired. With the loss, it is viewed that the company will report a loss in consolidated profit for the fiscal year ending March 31. Daiichi has previously estimated ¥65 billion in profit. It will be the first loss for the company since the merger of Daiichi and Sankyo in 2005. (Click here for more - Japanese language
You may also be interested in...
Daiichi Sankyo Looks At Consolidating Stake In Zenotech; Minority Shareholders, Founder Cry Hoarse
MUMBAI - Daiichi Sankyo, the majority equity holder in India's largest drug company Ranbaxy, has encountered a hurdle in its proposal to make an open offer for 20 percent shares in Zenotech Labs. Shareholders of Zenotech Labs have pleaded that the open offer price fixed by Daiichi Sankyo is far less than what Ranbaxy paid to acquire 46 percent of its equity a year ago
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.